Fig. 5: Pro-efferocytic SWNTs do not induce the hematologic abnormalities associated with anti-CD47 Ab therapy. | Nature Communications

Fig. 5: Pro-efferocytic SWNTs do not induce the hematologic abnormalities associated with anti-CD47 Ab therapy.

From: Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis

Fig. 5

a Pigs treated with SWNT-SHP1i do not develop anemia or thrombocytopenia, with no significant difference in CBC lab values (WBC, neutrophils, lymphocyte, monocyte) between the SWNT and SWNT-SHP1i treated cohorts at each timepoint. Data are presented as mean values ± SEM. SWNT and SWNT-SHP1i cohort per group n = 7 (Baseline), n = 7 (Month 1), n = 6 (Month 2), n = 5 (Month 3) from independent biological samples. b SWNT-SHP1i was not significantly associated with derangements in lipid levels compared to SWNT controls. Data are presented as mean values ± SEM. SWNT cohort n = 8 (Baseline), n = 7 (Month 1), n = 7 (Month 2), n = 6 (Month 3); SWNT-SHP1i cohort n = 7 (Baseline), n = 8 (Month 1), n = 7 (Month 2), n = 7 (Month 3) from independent biological samples. c, d SWNT-SHP1i was not associated with derangements in c renal function, or d hepatic function compared to SWNT treated controls. Data are presented as mean values ± SEM. SWNT cohort n = 8 (Baseline), n = 7 (Month 1), n = 7 (Month 2), n = 6 (Month 3); SWNT-SHP1i cohort n = 7 (Baseline), n = 7 (Month 1), n = 6 (Month 2), n = 6 (Month 3) from independent biological samples. e There was no significant difference in body weight between SWNT and SWNT-SHP1i treated pigs. Data are presented as mean values ± SEM. SWNT cohort n = 8 (Weeks 1–3), n = 7 (Weeks 4–8), n = 6 (Weeks 9–11), n = 3 (Week 12); SWNT-SHP1i cohort n = 7 (Weeks 1–4), n = 6 (Weeks 5–11), n = 4 (Week 12) from independent biological samples. Source data are provided as a Source data file.

Back to article page